心房功能性二尖瓣反流的手术策略与结局:所有功能性二尖瓣反流并不相同!
该研究回顾2000至2020年因二尖瓣反流行二尖瓣修复术的患者资料,排除退行性/黏液样病变、射血分数<50%及心内膜炎、风湿等病因,分离出123例「纯」心房功能性二尖瓣反流(AFMR)患者。术后中位569天超声随访显示72%(51/71)无或微量二尖瓣反流,仅1.6%(2/123)需再次二尖瓣手术,估计5年生存率74%。作者认为AFMR患者用成形环行二尖瓣修复后结局良好,二尖瓣成形术应考虑作为AFMR的首选外科治疗。
要点
- AFMR患者术前左房内径增大至4.9 cm,左室舒张末内径接近正常5.0 cm。
- 术后中位569天随访,72%(51/71)无或微量二尖瓣反流,仅6%(4/71)中重度以上。
- 仅1.6%(2/123)需再次二尖瓣手术,估计5年生存率74%。
核心结论
- AFMR患者使用成形环行二尖瓣修复后结局良好,再次手术率、死亡率及二尖瓣反流复发率均低。
- 作者认为二尖瓣成形术应考虑作为AFMR的首选外科治疗。
研究设计与样本
- 回顾性分析2000至2020年因二尖瓣反流行二尖瓣修复术患者的资料,排除退行性/黏液样病变、射血分数<50%及心内膜炎、风湿等病因,分离出123例「纯」AFMR患者,分析描述性特征与结局。
主要发现
- 123例AFMR患者术前平均左房内径增大至4.9 cm(95%CI,4.7-5.0),平均左室舒张末内径接近正常为5.0 cm(95%CI,4.9-5.2)。
- 术前心房颤动占61%(74/123)。
- 术后中位569天(四分位距75-1782天)行超声心动图者占58%(71/123),其中72%(51/71)无或微量二尖瓣反流,22%(16/71)轻度,仅6%(4/71)中重度以上。
- 仅1.6%(2/123)需再次二尖瓣手术,估计5年生存率74%。
临床怎么用
- 作者认为二尖瓣成形术应考虑作为AFMR的首选外科治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Functional mitral regurgitation (FMR) is a cardiac pathology that causes the mitral valve to malfunction, leading to mitral regurgitation (MR). The optimal strategy for FMR remains unclear, and FMR outcomes are poor. All etiologies of FMR might not be the same, and subdividing patients with FMR caused by atrial (AFMR) versus ventricular FMR pathology might be important. Herein, we present outcomes of patients with AFMR to define this "new" population. METHODS: Data of patients who underwent mitral valve repair for MR from 2000 to 2020 were reviewed. Patients with degenerative/myxomatous disease, ejection fraction <50% (ventricular FMR), and miscellaneous etiologies including endocarditis and rheumatic disease were excluded to isolate a population of "pure" AFMR patients. Descriptive characteristics and outcomes data were analyzed. RESULTS: Among 123 total AFMR patients, mean preoperative left atrial dimensions were enlarged to 4.9 (95% CI, 4.7-5.0) cm, whereas mean preoperative left ventricular diastolic dimensions remained near normal at 5.0 (95% CI, 4.9-5.2) cm. Preoperative atrial fibrillation was noted in 61% (74/123). Echocardiogram was performed in 58% (71/123) of patients at a median of 569 (interquartile range, 75-1782) days after surgery. Of those, 72% (51/71) had trivial or no MR, 22% (16/71) mild, and only 6% (4/71) moderate or greater MR. Only 1.6% (2/123) required redo mitral valve reoperation. Estimated 5-year survival was 74%. CONCLUSIONS: Patients with AFMR do well after mitral valve repair using an annuloplasty ring, with low rates of reoperation, mortality, and recurrence of MR. Mitral annuloplasty should be considered the surgical therapy of choice for AFMR.
引用
- Wagner CM, Brescia AA, Watt TMF, et al. Surgical strategy and outcomes for atrial functional mitral regurgitation: All functional mitral regurgitation is not the same! J Thorac Cardiovasc Surg. 2022. PMID: 35618531. doi:10.1016/j.jtcvs.2022.02.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。